Bortezomib
Title: Bortezomib
CAS Registry Number: 179324-69-7
CAS Name: [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid
Additional Names: N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid
Manufacturers' Codes: MG-341; PS-341
Trademarks: Velcade (Millenium)
Molecular Formula: C19H25BN4O4
Molecular Weight: 384.24
Percent Composition: C 59.39%, H 6.56%, B 2.81%, N 14.58%, O 16.66%
Literature References: Dipeptide boronic acid proteasome inhibitor. Prepn: J. Adams et al., WO 9613266; eidem, US 5780454 (1996, 1998 both to ProScript); idem et al., Bioorg. Med. Chem. Lett. 8, 333 (1998). Pharmacology and cytotoxic activity: idem et al., Cancer Res. 59, 2615 (1999). Crystal structure in complex with the yeast 20S proteasome: M. Groll et al., Structure 14, 451 (2006). Mechanism of action study: J. Codony-Servat et al., Mol. Cancer Ther. 5, 665 (2006). Clinical trial in refractory myeloma: P. G. Richardson et al., N. Engl. J. Med. 348, 2609 (2003). Review of clinical development: idem et al., Annu. Rev. Med. 57, 33-47 (2006).
Properties: Soly in water: 3.3-3.8 mg/ml (pH 2-6.5).
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic.

Others monographs:
TerbinafineBopindololSertralineMonoctanoin
HygrineMyristic AcidSodium Borate Solution CompoundIsonicotinic Acid Diethylamide
CyanazineMethyl BenzoateErabutoxinsSarafotoxins
Barium Sulfide, BlackChloramine-TIsoamyl ChlorideOcthilinone
©2016 DrugLead US FDA&EMEA